FDA Approves First Drug for GVHD after Stem Cell Transplant

August 3, 2017

(Medscape) – In a first, the US Food and Drug Administration (FDA) has approved a drug for use in patients who develop the life-threatening condition of chronic graft-vs-host disease (cGVHD) after having undergone a hematopoietic stem cell transplant (HSCT). This condition develops in about 30% to 70% of patients who undergo HSCT, which is a standard treatment for various leukemias and lymphomas.